Paper Key : IRJ************173
Author: Rote Shailesh Rajendra,Tandale Kiran Adinath
Date Published: 02 Dec 2024
Abstract
For a long time, the accepted treatment for glaucoma has been lowering intraocular pressure (IOP) through medication or surgery. There are several great medications on the market that can lower IOP. Usually, eye drops are used to administer these medications. However, patients may not comply to their treatment plans, which lowers the medicationsclinical efficacy. Current research is being done on a number of innovative delivery technologies intended to solve the problem of adherence and guarantee a steady decrease in IOP. Surgically implanted systems, injectables such biodegradable micro- and nanoparticles, and contact lens-releasing glaucoma medicines are some examples of these delivery methods. By providing a variety of administration modalities and having the ability to manage IOP over several months, these innovative technologies promise to increase clinical efficacy. Additionally, there is a wish to havein addition to IOP reduction, supplementary neuroprotective strategies for patients who still exhibit deterioration. For typical oral or drop formulations, many prospective neuroprotective drugs are unsuitable. The development of appropriate delivery mechanisms capable of delivering the medications to the retina and optic nerve in a localized, sustained manner is necessary to realize their promise. Drug delivery systems may enhance patient compliance, lessen adverse effects, boost effectiveness, and eventually help glaucoma sufferers maintain their vision. In this assessment, we go over the advantages and drawbacks of the existing distribution and application systems as well as those that are in the works.
DOI Requested